NCT02851784RecruitingPhase 2/3
Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
Combination Therapy of Microwave Ablation and Expanding Activated Autologous Lymphocytes for Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
The study is to observe safety, survival effect and peripheral T-lymphocyte subsets of combination therapy with percutaneous microwave ablation (MWA) and adoptive immunotherapy in hepatocellular carcinoma(HCC).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 25 Jul 2016
- Start date
- Dec 2009
- Primary completion date
- 30 Dec 2028
- Lead sponsor
- Chinese PLA General Hospital
- NCT number
- NCT02851784
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 80
- From Dec 2009 to the primary completion date, 30 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- active uncontrolled infection; concurrent systemic corticosteroid treatment;
- and chemotherapy or radiotherapy within the preceding 6 months
Other illness
- pregnant or breast-feeding; psychiatric problems, addiction, or any other disorder that prevented informed consent;
- systemic autoimmune disease;
- clinically significant ischemic heart disease or cardiac failure;
Who the study is looking for
- single HCC of 5 cm or smaller;
- three or fewer multiple HCC with a maximum dimension of 3 cm or less;
- absence of portal vein thrombosis or extrahepatic metastases;
- Child-Pugh classification A or B;
- tumor accessible via a percutaneous approach. white blood cell count \>2 x 109/L, platelet count \>40 x 109/L,serum creatinine \<110 μmol/L, aspartate aminotransferase \<3 times the upper limit, serum bilirubin \<2.5 times the upper limit, prothrombin time \<19 seconds.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chinese PLA General Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.